Intensity Therapeutics, Inc.
INTS
$3.70
-$0.04-1.01%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.64M | 1.18M | 1.16M | 1.21M | 1.24M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.14M | 2.73M | 2.71M | 3.39M | 3.20M |
| Operating Income | -3.14M | -2.73M | -2.71M | -3.39M | -3.20M |
| Income Before Tax | -3.05M | -2.67M | -2.54M | -3.35M | -3.18M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.05M | -2.67M | -2.54M | -3.35M | -3.18M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.05M | -2.67M | -2.54M | -3.35M | -3.18M |
| EBIT | -3.14M | -2.73M | -2.71M | -3.39M | -3.20M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.31 | -1.55 | -3.36 | -5.51 | -5.52 |
| Normalized Basic EPS | -0.82 | -0.97 | -2.10 | -3.45 | -3.45 |
| EPS Diluted | -2.62 | -1.55 | -3.36 | -5.51 | -5.52 |
| Normalized Diluted EPS | -0.82 | -0.97 | -2.10 | -3.45 | -3.45 |
| Average Basic Shares Outstanding | 2.33M | 1.72M | 754.70K | 606.90K | 576.00K |
| Average Diluted Shares Outstanding | 2.33M | 1.72M | 754.70K | 606.90K | 576.00K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |